Acute Porphyria Drug Database

M04AA01 - Allopurinol
Propably not porphyrinogenic
PNP

Rationale
Pyrimidine derivative. No data pointing to clinically significant CYP-induction. One reference consider it safe and one unsafe.
Chemical description
(To be edited, initial data ST OCT 04) Tablets; 100-600 mg/d. Pyrazolopyrimidine. Used in gout where it blocks the enzyme xantine oxidase, thus decreasing plasma levels of uric acid. Rapidly metabolized to oxypyrinol (alloxantine) and other metabolites. South African list: use. French list: interdit. C.Andersson; patient reports: tolerated (n=3).
IPNet drug reports
Uneventful use reported in 21 patients with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes M04A / M04AA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙